|
Microbix Biosystems, Inc. develops and manufactures biological products derived primarily from mammalian cell cultures. Focus technologies include biopharmaceuticals, vaccines and diagnostic reagents. Core is a team of development and manufacturing staff with significant expertise in cell culture and purification and has established itself as an internationally recognized source of infectious disease antigens and other specialty biological products. Products are designed for three main markets: biological generic pharmaceuticals, specialty and custom biologicals and veterinary vaccines. Currently, antigens are Microbix' major commercial product and Microbix produces some 40 antigen preparations derived form 19 different organisms. Current antigens include: Rubella, Toxoplasma, Dengue, Hepatitis, Varicella-Zoster, Mycoplasma pneumoniae, Chlamydia, CMV, and EBV.....With a view to developing higher value products, Microbix identified the emerging market for generic biotherapeutics as a significant opportunity for growth. We selected the protein drug urokinase as our first candidate for development as a generic.....Microbix concentrates on the development and manufacture of bulk biological products and, other than its core specialty biologicals business, pursues the commercialization of its products through licensing relationships with partners.
Activity:
- Licensing & Business Development
- Manufacturing
- Research & Development
Product / Technology type(s) covered:
- Bio
- Diagnostics
- Generics
- Pharmaceuticals / Therapeutics
- Reagents
- Technology
Therapeutic targets:
- Genetics
|
|
Company Contact
|
Microbix Biosystems Inc.
Canada
Phone:
FAX:
Website: www.microbix.com
|
|